Avalo Therapeutics (NASDAQ:AVTX) Raised to Strong-Buy at Wolfe Research

Key Points

• Wolfe Research upgraded Avalo to a "strong-buy," joining recent positive coverage — two analysts now rate it Strong Buy, six Buy and one Sell — with an average analyst target of $44.83.
• Shares trade around $14.21 (market cap ≈ $323.9M) with a 1‑year range of $3.39–$20.72, and the company recently beat quarterly EPS expectations (‑$0.37 vs. consensus ‑$1.54).
• Insiders have sold material stock in April under pre‑arranged Rule 10b5‑1 plans (46,100 shares sold last quarter), while institutional investors own about 87.06% of the company.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) was upgraded by research analysts at Wolfe Research to a "strong-buy" rating in a note issued to investors on Wednesday,Zacks.com reports.

AVTX has been the subject of several other reports. Guggenheim started coverage on Avalo Therapeutics in a report on Monday, February 2nd. They set a "buy" rating and a $50.00 target price for the company. Citizens Jmp started coverage on Avalo Therapeutics in a report on Monday. They set an "outperform" rating and a $52.00 target price for the company. HC Wainwright increased their target price on Avalo Therapeutics from $25.00 to $40.00 and gave the company a "buy" rating in a report on Wednesday, March 25th. Weiss Ratings restated a "sell (d-)" rating on shares of Avalo Therapeutics in a report on Friday, January 9th. Finally, Mizuho upgraded Avalo Therapeutics to a "strong-buy" rating in a report on Thursday, December 18th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $44.83.

Avalo Therapeutics Price Performance

Shares of AVTX stock opened at $14.21 on Wednesday. The stock has a market capitalization of $323.85 million, a PE ratio of -2.48 and a beta of 0.93. Avalo Therapeutics has a 1-year low of $3.39 and a 1-year high of $20.72. The business has a 50-day moving average of $15.52 and a 200 day moving average of $16.07.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last issued its earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($1.54) by $1.17. The company had revenue of $0.06 million for the quarter, compared to analysts' expectations of ($0.21) million. Analysts anticipate that Avalo Therapeutics will post -19.07 EPS for the current year.

Insider Activity at Avalo Therapeutics

In other Avalo Therapeutics news, insider Mittie Doyle sold 3,970 shares of the stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $18.01, for a total value of $71,499.70. Following the completion of the sale, the insider owned 3,622 shares in the company, valued at approximately $65,232.22. This trade represents a 52.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Ryan Sullivan sold 7,980 shares of the stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $17.15, for a total value of $136,857.00. Following the completion of the sale, the chief financial officer owned 17,338 shares of the company's stock, valued at approximately $297,346.70. This trade represents a 31.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 46,100 shares of company stock valued at $764,724. Company insiders own 3.03% of the company's stock.

Institutional Investors Weigh In On Avalo Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AVTX. Geode Capital Management LLC lifted its holdings in Avalo Therapeutics by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company's stock worth $552,000 after buying an additional 2,648 shares during the period. Nantahala Capital Management LLC lifted its stake in shares of Avalo Therapeutics by 10.6% in the 2nd quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company's stock valued at $4,965,000 after purchasing an additional 95,000 shares during the period. Bank of America Corp DE lifted its stake in shares of Avalo Therapeutics by 7,066.8% in the 2nd quarter. Bank of America Corp DE now owns 406,571 shares of the company's stock valued at $2,029,000 after purchasing an additional 400,898 shares during the period. Boothbay Fund Management LLC purchased a new position in shares of Avalo Therapeutics in the 2nd quarter valued at approximately $56,000. Finally, Aberdeen Group plc purchased a new position in shares of Avalo Therapeutics in the 3rd quarter valued at approximately $925,000. Hedge funds and other institutional investors own 87.06% of the company's stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.